The made-in India Covaxin vaccine, developed by Hyderabad-based Bharat Biotech, can neutralise the B1617 variant of coronavirus, said White House's chief medical adviser Dr Anthony Fauci.
"Now, this is something we are still gaining data on, but most recent data looking at convalescent sera of Covid-19 cases in people who received Covaxin, it was found to neutralise the 617 variant," Fauci was quoted as saying during the White House press briefing.
Fauci, who is US President Joe Biden's chief adviser on the Covid pandemic, quoted the recent Phase 3 clinical trials of Covaxin by ICMR, which claimed that the vaccine neutralises multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain (B1617) as well. He called "vaccination an important antidote".
"ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," the ICMR said in a tweet. The ICMR study also demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant.
It has been also successful in isolating and culturing the double mutant strain B1617 SARS-CoV-2 identified in certain regions of India and several other countries. "Covaxin has been found to effectively neutralise the double mutant strain as well," the ICMR said.
Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on January 3. Trial results later showed the vaccine has an efficacy of 78 percent.
The second-wave of coronavirus, which crippled India's healthcare system with lack of oxygen and others, highlighted global inequality, Fauci said, adding that countries have failed to unite to provide an adequate global response to prevent the "tragic" coronavirus outbreak from overwhelming India.
"The only way that you're going to adequately respond to a global pandemic is by having a global response, and a global response means equity throughout the world," the Guardian quoted Fauci as saying.
"And that's something that, unfortunately, has not been accomplished. Often when you have diseases in which there is a limited amount of intervention, be it therapeutic or prevention, this is something that all the countries that are relatively rich countries or countries that have a higher income have to pay more attention to," he added.
Responding to a question, Dr Andy Slavitt, White House COVID-19 Response Senior Advisor, said that a strike team from the Center for Disease Control and Prevention is headed over to India to help coordinate this response.
"We are making sure that we are locating some of the raw materials necessary to create more vaccines in India, which I think is going to be an important help there," he said.
"We stand with the country of India during this very trying and tragic surge. We are working to deploy resources and supplies, including therapeutics, rapid testing kits, ventilators, PPE, and raw materials, that are needed to manufacture vaccines in India, and the CDC, which has a long history of working with and in India on public health measures, will be deploying a strike team to the country to support the public health efforts there," Slavitt said.
Meanwhile, India recorded 360,960 new cases in the 24 hours to Wednesday morning according to Health Ministry data, another new daily global record. The ministry also said that India's total number of fatalities had passed 200,000 to stand at 201,187.
